Clinical studies have demonstrated that alogliptin produces rapid and sustained DPP-4 inhibition, improves both postprandial and fasting plasma glucose, and reduces glycated hemoglobin levels by approximately 0.5 to 1% after 12 to 26 weeks of treatment in adult T2DM patients [10–13]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.